Cargando…

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer

SIMPLE SUMMARY: Today, clinical management for the majority of cancer patients is still based on a “one-size-fits-all” approach. To improve the outcomes in the era of personalized medicine, it is essential to stratify patients based on established and novel biomarkers. In the present study, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfohl, Ulrike, Loskutov, Jürgen, Bashir, Sanum, Kühn, Ralf, Herter, Patrick, Templin, Markus, Mamlouk, Soulafa, Belanov, Sergei, Linnebacher, Michael, Bürtin, Florian, Vetter, Marcus, Reinhard, Christoph, Wedeken, Lena, Regenbrecht, Christian R. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265111/ https://www.ncbi.nlm.nih.gov/pubmed/35805024 http://dx.doi.org/10.3390/cancers14133252

Ejemplares similares

Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer
por: Sankarasubramanian, Sushmitha, et al.
Publicado: (2021)

Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
por: Pfohl, Ulrike, et al.
Publicado: (2021)

Photon and Proton irradiation in Patient-derived, Three-Dimensional Soft Tissue Sarcoma Models
por: Roohani, Siyer, et al.
Publicado: (2023)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Enhancement of CRISPR-Cas9 induced precise gene editing by targeting histone H2A-K15 ubiquitination
por: Bashir, Sanum, et al.
Publicado: (2020)

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras
por: Lauchle, Jennifer O., et al.
Publicado: (2009)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Robust in-silico identification of Cancer Cell Lines based on RNA and targeted DNA sequencing data
por: Otto, Raik, et al.
Publicado: (2019)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
por: Ahn, Soomin, et al.
Publicado: (2017)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Mouse models of colorectal cancer: Past, present and future perspectives
por: Bürtin, Florian, et al.
Publicado: (2020)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
por: Yoshioka, Ema, et al.
Publicado: (2018)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Enhancement of Precise Gene Editing by the Association of Cas9 With Homologous Recombination Factors
por: Tran, Ngoc-Tung, et al.
Publicado: (2019)

Corrigendum: Enhancement of Precise Gene Editing by the Association of Cas9 With Homologous Recombination Factors
por: Tran, Ngoc-Tung, et al.
Publicado: (2020)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

Mek1/2 Gene Dosage Determines Tissue Response to Oncogenic Ras Signaling in the Skin
por: Scholl, F A, et al.
Publicado: (2009)

The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA
por: Komatsu, Yumiko, et al.
Publicado: (2016)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors
por: Schmidt, Enrico K, et al.
Publicado: (2004)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Correction: The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2018)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_77s7m1pbtk452kvvi0p4ahkn88